27 results on '"Barley K"'
Search Results
2. Why hypocotyl extension mutants need to be characterized at the cell level: a case study of axr3-1
- Author
-
Barley, K.
- Published
- 2004
3. An emergency department intervention to protect an overlooked group of children at risk of significant harm
- Author
-
Kaye, P, Taylor, C, Barley, K, and Powell-Chandler, A
- Published
- 2009
- Full Text
- View/download PDF
4. EFFECTS OF SOIL TEMPERATURE AND PHOSPHORUS SUPPLY ON AN ANNUAL GRASS AND CLOVER GROWN IN MONOCULTURE AND IN MIXED CULTURE
- Author
-
VALENTINE, I. and BARLEY, K. P.
- Published
- 1976
5. The Effects of Mechanical Stress on the Growth of Roots
- Author
-
BARLEY, K. P.
- Published
- 1962
6. Modeling Ebola at the Mathematical and Theoretical Biology Institute (MTBI).
- Author
-
Castillo-Chavez, C., Barley, K., Bichara, D., Chowell, D., Herrera, E. Diaz, Espinoza, B., Moreno, V., Towers, S., and Yong, K. E.
- Published
- 2016
- Full Text
- View/download PDF
7. Effects of soil temperature and phosphorus supply on an annual grassand clover grown in monoculture and in mixed culture
- Author
-
Barley, K. P. and Valentine, I.
- Subjects
PHOSPHORUS ,SOIL temperature - Published
- 1976
8. Regression of smoldering myeloma with treatment of Gaucher disease.
- Author
-
Barley K, Parekh A, Salam S, Mendu DR, Shukla RP, Vatti D, Verina D, Stauffer C, Salib C, El Jamal S, Teruya-Feldstein J, Duffield AS, Leshchenko VV, Jagannath S, Balwani M, and Parekh S
- Subjects
- Humans, Disease Progression, Smoldering Multiple Myeloma, Gaucher Disease drug therapy, Multiple Myeloma diagnosis, Multiple Myeloma therapy
- Published
- 2024
- Full Text
- View/download PDF
9. A closer look at the spreaders of COVID-19 in Wisconsin and the US.
- Author
-
Scott SE, Cook KJ, and Barley K
- Subjects
- Asymptomatic Infections, Communicable Disease Control, Humans, SARS-CoV-2, United States, Wisconsin epidemiology, COVID-19
- Abstract
In this study, we design and use a mathematical model to primarily address the question of who are the main drivers of COVID-19 - the symptomatic infectious or the pre-symptomatic and asymptomatic infectious in the state of Wisconsin and the entire United States. To set the stage, we first briefly simulate and illustrate the benefit of lockdown. With these lockdown scenarios, and in general, the more dominant influence of the the pre-symptomatic and asymptomatic infectious over the symptomatic infectious, is shown in various ways. Numerical simulations for the U.S. show that an increase in testing and isolating for the pre-symptomatic and asymptomatic infectious group has up to 4 times more impact than an increase in testing for the symptomatic infectious in terms of cumulative deaths. An increase in testing for the pre-symptomatic and asymptomatic infectious group also has significantly more impact (on the order of twice as much) on reducing the control reproduction number than testing for symptomatic infectious. Lastly, we use our model to simulate an implementation of a natural herd immunity strategy for the entire U.S. and for the state of Wisconsin (once an epicenter for COVID-19). These simulations provide specific examples confirming that such a strategy requires a significant number of deaths before immunity is achieved, and as such, this strategy is certainly questionable in terms of success.
- Published
- 2021
- Full Text
- View/download PDF
10. Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review.
- Author
-
Sanchez L, Barley K, Richter J, Franz J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richard S, and Chari A
- Subjects
- Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Biomarkers, Tumor, Clinical Trials as Topic, Disease Management, Disease Susceptibility, Evidence-Based Practice, Humans, Multiple Myeloma diagnosis, Multiple Myeloma etiology, Multiple Myeloma mortality, Neoplasm Grading, Neoplasm Staging, Prognosis, Proteasome Inhibitors administration & dosage, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Molecular Targeted Therapy, Multiple Myeloma drug therapy
- Abstract
Introduction: Recent advances and drug approvals in the last decade have substantially changed the landscape of relapsed and refractory multiple myeloma (RRMM), which not only improved outcomes for patients but also increased complexity of treatment decisions. The approvals are based on randomized studies of novel agents added to an immunomodulatory drug- (IMiD) or proteasome inhibitor (PI)-backbone showing an improvement in outcomes. However, differences in enrolled patient populations/study designs limit comparisons of results, making the choice and sequencing of agents challenging., Areas Covered: This review summarizes the latest updates of key clinical trials of IMiD- and PI-backbone regimens in RRMM. Additionally, it highlights carfilzomib dosing strategies and toxicity profiles of varying carfilzomib combination regimens and provides a clinical guideline for the use of carfilzomib therapy. PubMed and relevant meeting (ASH, ASCO, EHA, IMW) databases from 2010 to 2020, as well as clinicaltrials.gov, were queried for this review., Expert Opinion: The choice of therapy for RRMM requires careful consideration of patient factors (age/frailty and comorbidities), disease factors (symptom burden/biology), and treatment-related factors (toxicities/responses to prior therapies). Importantly, a critical factor in selecting an agent based on the published data is a patient's sensitivity to lenalidomide and bortezomib at the time of relapse.
- Published
- 2020
- Full Text
- View/download PDF
11. Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m 2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m 2 .
- Author
-
Barley K, Sanchez L, Cho HJ, Parekh S, Madduri D, Richter J, Isola L, Goldstein T, Dhadwal A, Zarychta K, Sanchez GM, Catamero D, Verina D, Florendo E, Yum MH, La L, Gullie J, Chan E, Jagannath S, and Chari A
- Subjects
- Disease-Free Survival, Female, Humans, Male, Middle Aged, Oligopeptides adverse effects, Survival Rate, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Oligopeptides administration & dosage
- Published
- 2020
- Full Text
- View/download PDF
12. Video-Based Preconception Counseling for Women Living With HIV.
- Author
-
Alexander BM, Farel CE, Rahangdale L, McGee K, Thompson J, Barley K, and Harmon JL
- Subjects
- Adult, Feasibility Studies, Female, HIV Infections psychology, Humans, North Carolina, Pregnancy, Reproductive Health, Video Recording, Counseling methods, HIV Infections prevention & control, Health Knowledge, Attitudes, Practice, Patient Education as Topic methods, Preconception Care methods, Pregnancy Complications, Infectious prevention & control
- Published
- 2020
- Full Text
- View/download PDF
13. The effect of novel therapies in high-molecular-risk multiple myeloma.
- Author
-
Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, and Chari A
- Subjects
- Disease-Free Survival, Glycine therapeutic use, Humans, Kaplan-Meier Estimate, Multiple Myeloma diagnosis, Multiple Myeloma genetics, Panobinostat, Prognosis, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Boron Compounds therapeutic use, Glycine analogs & derivatives, Hydroxamic Acids therapeutic use, Indoles therapeutic use, Multiple Myeloma drug therapy, Oligopeptides therapeutic use
- Abstract
Multiple myeloma is a heterogeneous disease with a prognosis that varies with patient factors, disease burden, tumor biology, and treatments. Certain molecular abnormalities confer a worse prognosis and thus are considered high-risk. These include t(4;14), del(17p), t(14;16), t(14;20), hypodiploidy, and gain(1q)/del(1p). In our previous review in 2013, we discussed the effect of available therapies on prognosis in these high-risk patients. Since then, seven phase 3 clinical trials in relapsed myeloma with 1 to 3 lines of therapy have been conducted, resulting in the approval of panobinostat, ixazomib, daratumumab, and elotuzumab, as well as additional data on carfilzomib. In our current review of these studies, all the novel therapies resulted in an improvement in progression-free survival for high-risk patients, but none of the trials provided clear statistical evidence that they overcame high-risk status. Moreover, there are several limitations in the currently available data. For example, the patient's Revised International Staging System score is generally not reported, and even when it is reported, it is usually at the time of initial diagnosis rather than at the time of study entry. Furthermore, the methodology used to determine risk suffers from technologic issues. Finally, the clonal and allele burden and concurrent molecular abnormalities can affect risk status and prognosis. To determine the optimal therapy for high-risk patients, future clinical trials should provide standardized risk assessments for all patients in addition to hazard ratios for Kaplan-Meier survival curves of high-risk patients vs those of standard-risk patients to determine if high-risk status has truly been overcome by a novel agent.
- Published
- 2017
14. The role of mobility and health disparities on the transmission dynamics of Tuberculosis.
- Author
-
Moreno V, Espinoza B, Barley K, Paredes M, Bichara D, Mubayi A, and Castillo-Chavez C
- Subjects
- Humans, Tuberculosis diagnosis, Tuberculosis epidemiology, Disease Transmission, Infectious statistics & numerical data, Healthcare Disparities statistics & numerical data, Models, Theoretical, Travel statistics & numerical data, Tuberculosis transmission
- Abstract
Background: The transmission dynamics of Tuberculosis (TB) involve complex epidemiological and socio-economical interactions between individuals living in highly distinct regional conditions. The level of exogenous reinfection and first time infection rates within high-incidence settings may influence the impact of control programs on TB prevalence. The impact that effective population size and the distribution of individuals' residence times in different patches have on TB transmission and control are studied using selected scenarios where risk is defined by the estimated or perceive first time infection and/or exogenous re-infection rates., Methods: This study aims at enhancing the understanding of TB dynamics, within simplified, two patch, risk-defined environments, in the presence of short term mobility and variations in reinfection and infection rates via a mathematical model. The modeling framework captures the role of individuals' 'daily' dynamics within and between places of residency, work or business via the average proportion of time spent in residence and as visitors to TB-risk environments (patches). As a result, the effective population size of Patch i (home of i-residents) at time t must account for visitors and residents of Patch i, at time t., Results: The study identifies critical social behaviors mechanisms that can facilitate or eliminate TB infection in vulnerable populations. The results suggest that short-term mobility between heterogeneous patches contributes to significant overall increases in TB prevalence when risk is considered only in terms of direct new infection transmission, compared to the effect of exogenous reinfection. Although, the role of exogenous reinfection increases the risk that come from large movement of individuals, due to catastrophes or conflict, to TB-free areas., Conclusions: The study highlights that allowing infected individuals to move from high to low TB prevalence areas (for example via the sharing of treatment and isolation facilities) may lead to a reduction in the total TB prevalence in the overall population. The higher the population size heterogeneity between distinct risk patches, the larger the benefit (low overall prevalence) under the same "traveling" patterns. Policies need to account for population specific factors (such as risks that are inherent with high levels of migration, local and regional mobility patterns, and first time infection rates) in order to be long lasting, effective and results in low number of drug resistant cases.
- Published
- 2017
- Full Text
- View/download PDF
15. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
- Author
-
Barley K, He W, Agarwal S, Jagannath S, and Chari A
- Subjects
- Adrenal Cortex Hormones therapeutic use, Adult, Aged, Aged, 80 and over, Disease Management, Exanthema diagnosis, Female, Humans, Immunologic Factors therapeutic use, Lenalidomide, Male, Middle Aged, Multiple Myeloma diagnosis, Multiple Myeloma drug therapy, Retrospective Studies, Severity of Illness Index, Thalidomide adverse effects, Thalidomide therapeutic use, Treatment Outcome, Exanthema etiology, Exanthema therapy, Immunologic Factors adverse effects, Multiple Myeloma complications, Thalidomide analogs & derivatives
- Abstract
The immunomodulatory drugs thalidomide, lenalidomide, and pomalidomide (IMiDs) are an important component of myeloma treatment; one of six available drug classes for this incurable disease. Rash is a frequent side effect of IMiDs, particularly lenalidomide, often leading to treatment discontinuation. We retrospectively reviewed 52 patients (7.2% of patients seen during that time) with IMiD associated at a median of 3 weeks after exposure. Nearly all rashes were morbilliform, and 45% of evaluable rashes were grade 3-4 by NCI-CTCAE criteria. IMiDs were initially held in 33 patients (62%), and 25% received a short course of higher dose steroids. Seventy-nine percent of patients were reexposed to the same IMiD, often with dose reduction, and 57% were switched from weekly dexamethasone to thrice-weekly prednisone. Ninety-three percent of patients reexposed to the same IMiD with these interventions were able to tolerate and continue treatment, and only 14% had rash with reexposure, predominantly grade 1-2.
- Published
- 2016
- Full Text
- View/download PDF
16. Diagnostic Advances in Multiple Myeloma.
- Author
-
Barley K and Chari A
- Subjects
- Biomarkers, Tumor blood, Bone Marrow diagnostic imaging, Humans, Tomography, X-Ray Computed, Multiple Myeloma diagnosis
- Abstract
There have been several advances in the diagnosis of multiple myeloma (MM) in recent years. Serum free light chains have improved the ability to diagnose light chain MM; however, there are still difficulties in the serologic diagnosis of MM in some cases, particularly IgA MM. A novel heavy/light chain assay is able to improve the accuracy of diagnosis in these cases. Free light chains may also improve the diagnosis of extramedullary disease in difficult cases such as disease involving the central nervous system, pleura, or ascites. Advances in imaging such as whole body low-dose computed tomography (CT) whole body magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) have improved sensitivity in identifying lytic bone lesions, which would enable earlier treatment, and monitoring of osseous disease particularly in non- or oligosecretory disease. New techniques such as fused PET/MRI may further enhance the diagnosis of both bone lesions and extramedullary disease.
- Published
- 2016
- Full Text
- View/download PDF
17. Homo-psychologicus: Reactionary behavioural aspects of epidemics.
- Author
-
Cherif A, Barley K, and Hurtado M
- Subjects
- Computer Simulation, Humans, Models, Theoretical, Risk, Communicable Diseases psychology, Epidemics, Health Behavior, Health Knowledge, Attitudes, Practice, Models, Psychological
- Abstract
We formulate an in silico model of pathogen avoidance mechanism and investigate its impact on defensive behavioural measures (e.g., spontaneous social exclusions and distancing, crowd avoidance and voluntary vaccination adaptation). In particular, we use SIR(B)S (e.g., susceptible-infected-recovered with additional behavioural component) model to investigate the impact of homo-psychologicus aspects of epidemics. We focus on reactionary behavioural changes, which apply to both social distancing and voluntary vaccination participations. Our analyses reveal complex relationships between spontaneous and uncoordinated behavioural changes, the emergence of its contagion properties, and mitigation of infectious diseases. We find that the presence of effective behavioural changes can impede the persistence of disease. Furthermore, it was found that under perfect effective behavioural change, there are three regions in the response factor (e.g., imitation and/or reactionary) and behavioural scale factor (e.g., global/local) factors ρ-α behavioural space. Mainly, (1) disease is always endemic even in the presence of behavioural change, (2) behavioural-prevalence plasticity is observed and disease can sometimes be eradication, and (3) elimination of endemic disease under permanence of permanent behavioural change is achieved. These results suggest that preventive behavioural changes (e.g., non-pharmaceutical prophylactic measures, social distancing and exclusion, crowd avoidance) are influenced by individual differences in perception of risks and are a salient feature of epidemics. Additionally, these findings indicates that care needs to be taken when considering the effect of adaptive behavioural change in predicting the course of epidemics, and as well as the interpretation and development of the public health measures that account for spontaneous behavioural changes., (Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
18. Mathematical analysis of a model for AVL-HIV co-endemicity.
- Author
-
Hussaini N, Lubuma JM, Barley K, and Gumel AB
- Subjects
- Humans, Comorbidity, HIV Infections transmission, Leishmaniasis transmission, Models, Theoretical
- Abstract
A model for the transmission dynamics of Anthroponotic Visceral Leishmaniasis (AVL) and human immunodeficiency virus (HIV) in a population is developed and used to assess the impact of the spread of each disease on the overall transmission dynamics. As for other vector-borne disease models, the AVL component of the model undergoes backward bifurcation when the associated reproduction number of the AVL-only sub-model (denoted by RL) is less than unity. Uncertainty and sensitivity analyzes of the model, using data relevant to the dynamics of the two diseases in Ethiopia, show that the top three parameters that drive the AVL infection (with respect to the associated response function, RL) are the average number of times a sandfly bites humans per unit time (σV), carrying capacity of vectors (KV) and transmission probability from infected humans to susceptible sandflies (β2). The distribution of RL is RL∈[0.06,3.94] with a mean of RL=1.08. Furthermore, the top three parameters that affect HIV dynamics (with respect to the response function RH) are the transmission rate of HIV (βH), HIV-induced death rate (δH), and the modification parameter for the increase in infectiousness of AIDS individuals in comparison to HIV infected without clinical symptoms of AIDS (ωH). The distribution of RH is RH∈[0.88,2.79] with a mean of RH=1.46. The dominant parameters that affect the dynamics of the full VL-HIV model (with respect to the associated reproduction number, RLH, as the response function) are the transmission rate of HIV (βH), the average number of times a sandfly bites humans per unit time (σV), and HIV-induced death rate (δH) (the distribution of RLH is RLH∈[0.88,3.94] with a mean of RLH=1.64). Numerical simulations of the model show that the two diseases co-exist (with AVL dominating, but not driving HIV to extinction) whenever the reproduction number of each disease exceeds unity. It is shown that AVL can invade a population at HIV-endemic state if a certain threshold quantity, known as invasion reproduction number, exceeds unity., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
19. Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma.
- Author
-
Barley K, Tindle S, Bagiella E, Jagannath S, and Chari A
- Subjects
- Adult, Aged, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local pathology, Prognosis, Retrospective Studies, Stem Cell Transplantation methods, Transplantation Conditioning methods, Transplantation, Autologous methods, Immunoglobulin Light Chains blood, Multiple Myeloma blood, Multiple Myeloma pathology
- Abstract
Background: Multiple myeloma is an incurable cancer commonly treated with stem cell transplantation (SCT). Response is traditionally evaluated 100 days after SCT, both to allow for hematopoietic reconstitution and due to immunoglobulins' long half-lives. Free light chains (FLC) have significantly shorter half-lives and may provide evidence of response or treatment failure earlier after SCT., Patients and Methods: We retrospectively studied 83 consecutive patients with multiple myeloma who underwent SCT and found 69 who had FLC measured 30 or 60 days after SCT. Using conventional FLC response criteria, we considered a patient to be at high risk for early relapse if he or she failed to experience a partial response by day 30 or 60., Results: After a median overall follow-up of only 335 days, these high-risk patients had significantly shorter progression-free survival (median, 98 vs. 335 days, P = .001) and overall survival (366 days vs. median not reached, P = .016)., Conclusion: Early FLC assessment either 1 or 2 months after SCT using standard FLC response criteria was able to identify a subset of patients at high risk of early relapse, and these patients may benefit from earlier interventions., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
20. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
- Author
-
Chari A, Barley K, Jagannath S, and Osman K
- Subjects
- Adult, Aged, Angiogenesis Inhibitors administration & dosage, Angiogenesis Inhibitors adverse effects, Boronic Acids administration & dosage, Boronic Acids adverse effects, Bortezomib, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Female, Follow-Up Studies, Humans, Lenalidomide, Male, Middle Aged, Pyrazines administration & dosage, Pyrazines adverse effects, Retrospective Studies, Stem Cell Transplantation methods, Thalidomide administration & dosage, Thalidomide adverse effects, Thalidomide analogs & derivatives, Treatment Outcome, Amyloidosis drug therapy, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
Background: The prognosis of patients with systemic light chain (AL) amyloidosis, particularly cardiac, is poor. Treatments have been derived from multiple myeloma, but there are few studies that use triplet regimens in AL amyloidosis because of concern of greater toxicity than seen in myeloma., Patients and Methods: We conducted a retrospective review of patients with newly diagnosed AL amyloidosis who were initially treated with a triplet regimen., Results: For the 9 patients included, the median age was 64 years, and 8 were ineligible for stem cell transplantation. At least 2 organs were involved in 4 patients, including 7 with kidney and 4 with heart involvement, 2 of whom had New York Heart Association class 3 heart failure. All the patients received bortezomib, cyclophosphamide or lenalidomide/thalidomide, and dexamethasone. With a median follow-up of 13 months, 8 of 9 patients had a hematologic response, including 2 who achieved complete response, with a median time to response of 2.7 months. An organ response was seen in 7 of 9 patients, including all 4 patients with cardiac involvement. There were no deaths, and only 1 patient had progressive disease. The major toxicity observed was fluid overload and syncope, seen only in patients with heart failure, who eventually achieved a partial or complete response., Conclusions: Dose-attenuated triplet regimens achieved rapid hematologic responses with manageable and reversible toxicity in patients with newly diagnosed AL amyloidosis., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
21. Misdiagnosis of non-hodgkin lymphoma as multiple myeloma.
- Author
-
Barley K, Harris JA, Diefenbach C, Jagannath S, and Chari A
- Subjects
- Diagnosis, Differential, Humans, Male, Middle Aged, Multiple Myeloma pathology, Diagnostic Errors, Lymphoma, Non-Hodgkin diagnosis, Multiple Myeloma diagnosis
- Published
- 2012
- Full Text
- View/download PDF
22. Cliophysics: socio-political reliability theory, polity duration and African political (in)stabilities.
- Author
-
Cherif A and Barley K
- Subjects
- Africa, Developing Countries, Economics, Humans, Models, Statistical, Population, Socioeconomic Factors, Democracy, Political Systems, Politics
- Abstract
Quantification of historical sociological processes have recently gained attention among theoreticians in the effort of providing a solid theoretical understanding of the behaviors and regularities present in socio-political dynamics. Here we present a reliability theory of polity processes with emphases on individual political dynamics of African countries. We found that the structural properties of polity failure rates successfully capture the risk of political vulnerability and instabilities in which , , , and of the countries with monotonically increasing, unimodal, U-shaped and monotonically decreasing polity failure rates, respectively, have high level of state fragility indices. The quasi-U-shape relationship between average polity duration and regime types corroborates historical precedents and explains the stability of the autocracies and democracies.
- Published
- 2010
- Full Text
- View/download PDF
23. Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia.
- Author
-
Kerns D, Vong GS, Barley K, Dracheva S, Katsel P, Casaccia P, Haroutunian V, and Byne W
- Subjects
- Adult, Age Factors, Analysis of Variance, Basic Helix-Loop-Helix Transcription Factors genetics, Calcium-Binding Proteins genetics, Cyclin D1 genetics, Cyclin D2 genetics, Female, Homeodomain Proteins genetics, Humans, Intercellular Signaling Peptides and Proteins genetics, Jagged-1 Protein, Male, Membrane Proteins genetics, Middle Aged, RNA, Messenger metabolism, Serrate-Jagged Proteins, Statistics as Topic, Transcription Factor HES-1, Caspase 3 genetics, Gene Expression Regulation genetics, Internal Capsule pathology, Oligodendroglia pathology, Proliferating Cell Nuclear Antigen genetics, Receptors, Notch genetics, Schizophrenia genetics, Schizophrenia pathology, Signal Transduction genetics
- Abstract
Deficits in the expression of oligodendrocyte (Ol) and myelin genes have been described in numerous brain regions in schizophrenia (SZ) in association with abnormalities of cell cycle markers. We have previously reported a SZ-associated decrease in the expression of genes expressed after, but not prior to, the terminal differentiation of Ols in the posterior limb of the internal capsule (ICp). This pattern of deficits could reflect a failure of Ol precursors to exit the cell cycle and differentiate to meet the demands imposed by the high rate of apoptosis among myelinating Ols. Here we explore this hypothesis using quantitative real time PCR to examine the mRNA expression of additional genes in the ICp of the previously examined sample of 14 subjects with SZ and 15 normal controls (NCs). The genes examined in the present study were chosen because they are associated with particular phases of the cell cycle (CCND1, CCND2, p21(Cip1), p27(Kip1), and p57(Kip2)), with DNA replication and repair (PCNA), apoptosis (CASP3), or the Notch signaling pathway (JAG1, HES1, HES5, andDTX1). The Notch pathway influences whether Ol precursors continue to proliferate or exit the cell cycle. We also determined the densities of Ols in the ICp. Genes associated with maintenance of the cell cycle tended to exhibit increased expression levels in SZ relative to NCs and to be negatively correlated with the expression levels of the previously assessed mature Ol genes. In contrast, genes associated with cell cycle arrest tended to show the opposite pattern (decreased expression in SZ and positive correlations with mature Ol genes). CASP3 and PCNA expression levels were significantly decreased in SZ and positively correlated with mature Ol genes, suggesting that myelinating Ols may turnover more rapidly in normal controls than in subjects with SZ. JAG1 expression was significantly increased in SZ and exhibited positive correlations with mediators of the canonical Notch pathway but negative correlations with mature Ol genes. Ol densities were significantly decreased in SZ. These data are consistent with the hypothesis that Ol and myelin deficits in SZ involve a failure of Ol precursors to appropriately exit the cell cycle in order to differentiate and mature into myelinating Ols., ((c) 2010 Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
24. HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells.
- Author
-
Snyder A, Alsauskas ZC, Leventhal JS, Rosenstiel PE, Gong P, Chan JJ, Barley K, He JC, Klotman ME, Ross MJ, and Klotman PE
- Subjects
- AIDS-Associated Nephropathy genetics, AIDS-Associated Nephropathy virology, Apoptosis genetics, Caspase 8 genetics, Cell Proliferation, Gene Expression Regulation, Viral, Gene Products, vpr genetics, Humans, Kidney Failure, Chronic genetics, Kidney Failure, Chronic virology, Kidney Tubules virology, RNA, Viral, Virus Replication, AIDS-Associated Nephropathy metabolism, Apoptosis physiology, Caspase 8 metabolism, Extracellular Signal-Regulated MAP Kinases metabolism, Gene Products, vpr metabolism, HIV-1, Kidney Failure, Chronic metabolism
- Abstract
Objective: HIV-associated nephropathy (HIVAN) is the most common cause of end-stage renal disease in persons with HIV/AIDS and is characterized by focal glomerulosclerosis and dysregulated renal tubular epithelial cell (RTEC) proliferation and apoptosis. HIV-1 viral protein r (Vpr) has been implicated in HIV-induced RTEC apoptosis but the mechanisms of Vpr-induced RTEC apoptosis are unknown. The aim of this study was therefore to determine the mechanisms of Vpr-induced apoptosis in RTEC., Methods: Apoptosis and caspase activation were analyzed in human RTEC (HK2) after transduction with Vpr-expressing and control lentiviral vectors. Bax and BID were inhibited with lentiviral shRNA, and ERK activation was blocked with the MEK1,2 inhibitor, U0126., Results: Vpr induced apoptosis as indicated by caspase 3/7 activation, PARP-1 cleavage and mitochondrial injury. Vpr activated both caspases-8 and 9. Inhibition of Bax reduced Vpr-induced apoptosis, as reported in other cell types. Additionally, Vpr-induced cleavage of BID to tBID and suppression of BID expression prevented Vpr-induced apoptosis. Since sustained ERK activation can activate caspase-8 in some cell types, we studied the role of ERK in Vpr-induced caspase-8 activation. Vpr induced sustained ERK activation in HK2 cells and incubation with U0126 reduced Vpr-induced caspase-8 activation, BID cleavage and apoptosis. We detected phosphorylated ERK in RTEC in HIVAN biopsy specimens by immunohistochemistry., Conclusions: These studies delineate a novel pathway of Vpr-induced apoptosis in RTEC, which is mediated by sustained ERK activation, resulting in caspase 8-mediated cleavage of BID to tBID, thereby facilitating Bax-mediated mitochondrial injury and apoptosis.
- Published
- 2010
- Full Text
- View/download PDF
25. Editing of serotonin 2C receptor mRNA in the prefrontal cortex characterizes high-novelty locomotor response behavioral trait.
- Author
-
Dracheva S, Lyddon R, Barley K, Marcus SM, Hurd YL, and Byne WM
- Subjects
- Adenosine Deaminase genetics, Animals, Behavior, Animal physiology, Gene Knock-In Techniques methods, Humans, Male, Nucleus Accumbens metabolism, Phenotype, RNA-Binding Proteins, Rats, Rats, Sprague-Dawley, Statistics as Topic, Ventral Tegmental Area metabolism, Exploratory Behavior physiology, Gene Expression Regulation physiology, Prefrontal Cortex physiology, RNA Editing physiology, RNA, Messenger genetics, Receptor, Serotonin, 5-HT2C genetics
- Abstract
Serotonin 2C receptor (5-HT(2C)R) exerts a major inhibitory influence on dopamine (DA) neurotransmission within the mesocorticolimbic DA pathway that is implicated in drug reward and goal-directed behaviors. 5-HT(2C)R pre-mRNA undergoes adenosine-to-inosine editing, generating numerous receptor isoforms in brain. As editing influences 5-HT(2C)R activity, individual differences in editing might influence dopaminergic function and, thereby, contribute to interindividual vulnerability to drug addiction. Liability to drug-related behaviors in rats can be predicted by their level of motor activity in response to a novel environment. Rats with a high locomotor response (high responders; HRs) exhibit enhanced acquisition and maintenance of drug self-administration compared to rats with a low response (low responders; LRs). We here examined 5-HT(2C)R mRNA editing and expression in HR and LR phenotypes to investigate the relationship between 5-HT(2C)R function and behavioral traits relevant to drug addiction vulnerability. Three regions of the mesocorticolimbic circuitry (ventral tegmental area (VTA), nucleus accumbens (NuAc) shell, and medial prefrontal cortex (PFC)) were examined. 5-HT(2C)R mRNA expression and editing were significantly higher in the NuAc shell compared with both the PFC and VTA, implying significant differences in function (including constitutive activity) among 5-HT(2C)R neuronal populations within the circuitry. The regional differences in editing could, at least in part, arise from the variations in expression levels of the editing enzyme, ADAR2, and/or from the variations in the ADAR2/ADAR1 ratio observed in the study. No differences in the 5-HT(2C)R expression were detected between the behavioral phenotypes. However, editing was higher in the PFC of HRs vs LRs, implicating this region in the pathophysiology of drug abuse liability.
- Published
- 2009
- Full Text
- View/download PDF
26. Subcortical oligodendrocyte- and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder.
- Author
-
Barley K, Dracheva S, and Byne W
- Subjects
- Adult, Aldehyde Dehydrogenase genetics, Aldehyde Dehydrogenase 1 Family, Analysis of Variance, Astrocytes metabolism, Bipolar Disorder metabolism, Bipolar Disorder pathology, Depressive Disorder, Major metabolism, Depressive Disorder, Major pathology, Female, Functional Laterality, Glial Fibrillary Acidic Protein genetics, Humans, Isoenzymes genetics, Male, Middle Aged, Oligodendroglia metabolism, RNA, Messenger metabolism, Retinal Dehydrogenase, Schizophrenia metabolism, Schizophrenia pathology, Sex Factors, Aldehyde Dehydrogenase metabolism, Bipolar Disorder genetics, Brain metabolism, Brain pathology, Brain physiopathology, Depressive Disorder, Major genetics, Gene Expression Regulation physiology, Glial Fibrillary Acidic Protein metabolism, Isoenzymes metabolism, Schizophrenia genetics
- Abstract
Deficits in the expression of oligodendrocyte and myelin genes have been described in numerous cortical regions in schizophrenia and affective disorders; however, relatively little attention has been paid to subcortical structures. Here we employed quantitative real time PCR to examine the mRNA expression of 17 genes that are expressed by oligodendrocyte precursors (OLPs) and their derivatives, including astrocytes. Four subcortical regions were examined (the anteroventral (AV) and mediodorsal thalamic nuclei (MDN), internal capsule (IC) and putamen (Put)) in postmortem material from subjects (age 25-68 at time of death) with no known psychiatric history (NCs) as well as in subjects with schizophrenia (SZ), major depressive disorder (MDD), and bipolar disorder (BPD). In all regions examined, genes expressed after the terminal differentiation of oligodendrocytes tended to have lower levels of mRNA expression in subjects with SZ compared to NCs. These differences were statistically significant across regions for four genes (CNP, GALC, MAG and MOG) and approached significance for TF. No genes were under expressed in MDD. Only TF was under expressed in BPD and only in the IC. In contrast, two astrocyte-associated genes (GFAP and ALDH1L1) had higher mean expression levels across regions in all psychiatric groups relative to NCs. These differences reached statistical significance for SZ and MDD relative to NCs. There were no age by diagnosis interactions. The majority of age regressions had negative slopes for the expression of oligodendrocyte-associated genes. GFAP but not ALDH1L1 expression was significantly and positively correlated with age in the MDN, AV and Put. Across subject groups the expression of both astrocyte genes was highly correlated with cumulative neuroleptic exposure in all regions except the Put. Significant positive correlations were also observed in some regions between cumulative neuroleptic exposure and the expression of genes associated with mature oligodendrocytes as well as with bipotential OLPs. Multiple negative correlations were observed between the mRNA expression of astrocyte genes and genes expressed by terminally differentiated oligodendrocytes. These data are discussed in the context of myelin turnover and potential effects of psychiatric illness as well as medications on the developmental fate of OLPs.
- Published
- 2009
- Full Text
- View/download PDF
27. Social class and elective caesareans in the English NHS.
- Author
-
Barley K, Aylin P, Bottle A, and Jarman B
- Subjects
- Adolescent, Adult, Age Factors, Female, Humans, Middle Aged, Odds Ratio, Pregnancy, State Medicine, United Kingdom, Cesarean Section statistics & numerical data, Elective Surgical Procedures statistics & numerical data, Social Class
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.